Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -20.67% is in line with its 4-year average of -20.45%, near the low end of its 4-year range (-24.39%–-11.66%).
29.19% below its 12-month average of -16.00%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -7.28%.
RETURN ON ASSETS (ROA)
-20.67%
RETURN ON ASSETS (ROA) AVG TTM
-16.00%
RETURN ON ASSETS (ROA) AVG 3Y
-20.09%
RETURN ON ASSETS (ROA) AVG 5Y
N/A
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-29.19%
CURRENT VS 3Y AVG
-2.86%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
+35.89%
vs the sector median at left
CG Oncology Inc.
Market Cap
$5.61B
Return on Assets (ROA)
-20.67%
TTM Avg
-16.00%
3Y Avg
-20.09%
5Y Avg
N/A
Market Cap
$5.53B
Return on Assets (ROA)
-0.50%
TTM Avg
-0.21%
3Y Avg
0.03%
5Y Avg
0.08%
Market Cap
$5.52B
Return on Assets (ROA)
-6.97%
TTM Avg
-6.55%
3Y Avg
-3.96%
5Y Avg
-3.96%
Market Cap
$5.78B
Return on Assets (ROA)
-94.23%
TTM Avg
-58.97%
3Y Avg
-55.59%
5Y Avg
-44.06%
Market Cap
$5.79B
Return on Assets (ROA)
-31.62%
TTM Avg
-41.85%
3Y Avg
-50.05%
5Y Avg
-46.34%
Market Cap
$5.87B
Return on Assets (ROA)
9.00%
TTM Avg
0.15%
3Y Avg
10.71%
5Y Avg
-11.86%
Market Cap
$5.89B
Return on Assets (ROA)
-13.77%
TTM Avg
-40.95%
3Y Avg
-52.61%
5Y Avg
-44.58%
Market Cap
$5.32B
Return on Assets (ROA)
-1.18%
TTM Avg
1.12%
3Y Avg
-15.90%
5Y Avg
-18.41%
Market Cap
$5.95B
Return on Assets (ROA)
9.02%
TTM Avg
3.77%
3Y Avg
2.45%
5Y Avg
2.33%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CG Oncology Inc. (CGON) | $5.61B | -20.67% | -16.00% | -20.09% | N/A |
| RadNet, Inc. (RDNT)vs › | $5.53B | -0.50% | -0.21% | 0.03% | 0.08% |
| MiniMed Group, Inc. Common Stock (MMED)vs › | $5.52B | -6.97% | -6.55% | -3.96% | -3.96% |
| Kodiak Sciences Inc. (KOD)vs › | $5.78B | -94.23% | -58.97% | -55.59% | -44.06% |
| Iovance Biotherapeutics, Inc. (IOVA)vs › | $5.79B | -31.62% | -41.85% | -50.05% | -46.34% |
| Kiniksa Pharmaceuticals International, plc (KNSA)vs › | $5.87B | 9.00% | 0.15% | 10.71% | -11.86% |
| GRAIL Inc. (GRAL)vs › | $5.89B | -13.77% | -40.95% | -52.61% | -44.58% |
| PTC Therapeutics, Inc. (PTCT)vs › | $5.32B | -1.18% | 1.12% | -15.90% | -18.41% |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $5.95B | 9.02% | 3.77% | 2.45% | 2.33% |
| CRISPR Therapeutics AG (CRSP)vs › | $5.21B | -17.02% | -21.01% | -19.47% | -13.88% |
ROA
-20.7%
ROE
-21.8%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -20.34% |
| 2024-12-31 | -11.66% |
| 2023-12-31 | -24.39% |
| 2022-12-31 | -23.99% |
| 2021-12-31 | -21.88% |
